Brinda Desai,Muhammad Adrish,Arjun Mohan et al.
Brinda Desai et al.
Advances in our understanding of asthma pathophysiology have led to the advent of multiple targeted asthma therapies such as biologics. However, partial response to biologics occurs, indicating residual disease activity in some patients. He...
Real-World Studies of Biologics for the Treatment of Moderate-to-Severe Asthma [0.03%]
生物制剂治疗中重度哮喘的现实世界研究
Mauli Desai,Adam Haines,John J Oppenheimer
Mauli Desai
Presently, there are 6 biologic agents available for treatment of asthma. Each of these agents has undergone robust clinical trials in their approval programs. Such studies rely upon very rigid entry criteria that may not translate to real-...
Orlando Rivera nd,Rohit Katial,Flavia C L Hoyte
Orlando Rivera nd
Establishing a universal definition for asthma remission has the potential to improve asthma outcomes and advance research. However, there is still no consensus definition despite broad multidisciplinary efforts to achieve this goal. This s...
Gabriel Lavoie,Ian D Pavord
Gabriel Lavoie
Our modern understanding of asthma mainly concerns identification of inflammatory endotype to guide management. The distinction mostly concerns identification of type-2 inflammation, for which different biomarkers have been well characteriz...
Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations [0.03%]
哮喘生物制剂：肺功能、激素依赖性和病情加重
Justin D Salciccioli,Elliot Israel
Justin D Salciccioli
The development of multiple targeted biologic therapies over the past two decades has revolutionized the management of asthma. Currently, there are 6 monoclonal antibodies that target specific inflammatory mediators involved in the pathophy...
Biologics in Aspirin-Exacerbated Respiratory Disease and Allergic Bronchopulmonary Aspergillosis [0.03%]
生物制剂在阿司匹林加重呼吸系统疾病和过敏性支气管肺曲霉病中的应用
Jenny Huang,Andrew A White
Jenny Huang
Biologic medications have dramatically altered the landscape for treatment of allergic conditions including aspirin-exacerbated respiratory disease (AERD) and allergic bronchopulmonary aspergillosis (ABPA). Biologics should be considered fo...
Jacob T Boyd,Ashoke R Khanwalkar
Jacob T Boyd
Chronic rhinosinusitis (CRS) is categorized phenotypically into CRS with and without nasal polyps (CRSwNP, CRSsNP). Endotyping categorizes the disease based on immune cell activity and inflammatory mechanisms into Type 1, Type 2, and Type 3...
Michele Beaudoin,Chloe Citron,Kanwaljit K Brar
Michele Beaudoin
Immunoglobuin E (IgE)-mediated food allergies greatly impact patients and their families, causing financial and emotional stress, and placing them at risk for lifethreatening reactions. Until recently, food allergies have been treated with ...
Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis [0.03%]
高嗜酸性粒细胞综合征和嗜酸细胞性肉芽肿伴血管炎中的生物制剂治疗
Ejiofor Ezekwe,Andrew L Weskamp,Luke M Pittman et al.
Ejiofor Ezekwe et al.
Hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA) are complex disorders defined by blood and tissue eosinophilia and heterogeneous clinical manifestations. Historically, the mainstay of therapy for bo...
Advancements in Biologic Therapies for Eosinophilic Gastrointestinal Diseases: A Comprehensive Review [0.03%]
生物制剂治疗嗜酸细胞性胃肠病的研究进展：全面综述
Racha Abi Melhem,Yasmin Hassoun
Racha Abi Melhem
Eosinophilic gastrointestinal diseases (EGIDs) encompass a group of disorders characterized by an abnormal accumulation of eosinophils in various parts of the gastrointestinal tract. EGIDs present with a wide range of symptoms such as abdom...